Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin and Metformin for Cognitive Function in Type 2 Diabetes
NCT05262257Phase 1Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Event-related potential at 12 weeks, Montreal Cognitive Assessment at 12 weeks and 1 more. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05262257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262257.